A brief history of and future prospects for pneumococcal vaccination in Malaysia

A brief history of and future prospects for pneumococcal vaccination in Malaysia

Abstract Pneumococcal pneumonia remains a significant global public health issue. Malaysia has recently added the 10 valent pneumococcal conjugate vaccine to its national immunisation programme. Data on pneumococcal serotype epidemiology is vital for informing national vaccination policy. However, t...

Full description

Bibliographic Details
Main Authors:	Alex J. J. Lister, Evelin Dombay, David W. Cleary, Lokman H. Sulaiman, Stuart C. Clarke
Format:	Article
Language:	English
Published:	BMC 2023-08-01
Series:	Pneumonia
Subjects:	Pneumococcal disease Pneumococcal vaccination Malaysia Vaccination policy Pneumonia
Online Access:	https://doi.org/10.1186/s41479-023-00114-8

Similar Items

Strategies for pneumococcal vaccination in older adults in the coming era
by: Kei Nakashima, et al.
Published: (2024-12-01)

A Multicomponent Intervention to Improve Pneumococcal Vaccination Knowledge Among Internal Medicine Residents
by: Matthew W. Wilson, et al.
Published: (2016-06-01)

Evaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017–2018
by: Angel Vila-Córcoles, et al.
Published: (2023-04-01)

CLINICAL AND EPIDEMIOLOGICAL ASSESSMENT OF THE EFFECTIVENESS OF VACCINATION OF CHILDREN AGAINST PNEUMOCOCCAL INFECTION IN THE AMUR REGION
by: A. G. Chuchalin, et al.
Published: (2016-06-01)

Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?
by: Cornelis H. van Werkhoven
Published: (2017-05-01)

23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type <i>Streptococcus pneumoniae</i>
by: Thomas Chandler, et al.
Published: (2022-03-01)

Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
by: Salil Bendre, et al.
Published: (2024-02-01)

Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
by: Salil Bendre, et al.
Published: (2024-02-01)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01)

Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults
by: Jennifer L. Farrar, et al.
Published: (2023-05-01)

The Role of Serotype-Specific Immunological Memory in Pneumococcal Vaccination: Current Knowledge and Future Prospects
by: Ioanna Papadatou, et al.
Published: (2019-01-01)

Pneumococcal meningitis: epidemiological profile pre‐ and post‐introduction of the pneumococcal 10‐valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015-03-01)

Pneumococcal Disease: Global Disease Prevention Strategies with a Focus on the Challenges in Iraq
by: Al-Jumaili A, et al.
Published: (2023-05-01)

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
by: Hyunju Lee, et al.
Published: (2014-02-01)

Pneumococcal Serogroups Causing the Most of the Invasive Diseases in Kayseri
by: Duygu EŞEL, et al.
Published: (2002-03-01)

Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States
by: Andrew D. Wiese, et al.
Published: (2019-04-01)

Immunological and Epidemiological Aspects of the Immunogenicity of Streptococcus Pneumoniae Serotype 3 Capsular Polysaccharide in Pneumococcal Vaccines
by: A. E. Zaitsev, et al.
Published: (2020-04-01)

A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population
by: Jacob Dag Berild, et al.
Published: (2020-04-01)

Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine
by: Antoni Payeras, et al.
Published: (2015-04-01)

Incidence of pneumococcal disease from 2003 to 2019 in children ≤17 years in England
by: Salini Mohanty, et al.
Published: (2023-01-01)

Haemophilus influenzae type b and pneumococcal conjugate vaccination coverage in children aged 2-59 months in Malawi
by: Daphne Gadama, et al.
Published: (2021-02-01)

Routine infant vaccination of pneumococcal conjugate vaccines has decreased pneumonia across all age groups in Northern Spain
by: I. Rivero-Calle, et al.
Published: (2020-06-01)

Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world
by: Yadong A. Cui, et al.
Published: (2017-06-01)

Adult pneumococcal vaccination – new opportunities
by: ERNEST KUCHAR, et al.
Published: (2023-03-01)

Economic aspects of hospital treated pneumococcal pneumonia and the results of Pneumo 23 vaccine use in Serbia
by: Adžić Tatjana, et al.
Published: (2008-01-01)

Increased Invasive Pneumococcal Disease, North East England, UK
by: Catherine Houseman, et al.
Published: (2017-01-01)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
by: Hye-Young Kim, et al.
Published: (2021-03-01)

Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea
by: Deborah Lehmann, et al.
Published: (2017-12-01)

Recent progress in pneumococcal protein vaccines
by: Sha Li, et al.
Published: (2023-09-01)

Childhood invasive pneumococcal disease caused by non-7-valent pneumococcal vaccine (PCV7) serotypes under partial immunization in Taiwan
by: Ching-Fen Shen, et al.
Published: (2013-09-01)

Pneumococcal whole-cell and protein-based vaccines: changing the paradigm
by: Michael E. Pichichero
Published: (2017-12-01)

Serotype distribution of Streptococcus pneumoniae and potential impact of pneumococcal conjugate vaccines in China: A systematic review and meta-analysis
by: Kaile Chen, et al.
Published: (2018-06-01)

A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom
by: James Campling, et al.
Published: (2023-12-01)

Effect of different schedules of ten-valent pneumococcal conjugate vaccine on pneumococcal carriage in Vietnamese infants: results from a randomised controlled trialResearch in context
by: Heidi Smith-Vaughan, et al.
Published: (2023-03-01)

Pneumococcal vaccination in adult patients with comorbidities: a review of the clinical practice guidelines
by: Kozlov R.S., et al.
Published: (2020-12-01)

Efficacy of pneumococcal vaccine in immunocompetent and immunocompromised patients
by: M. P. Kostinov, et al.
Published: (2019-11-01)

Changes in Childhood Pneumonia Hospitalizations by Race and Sex Associated with Pneumococcal Conjugate Vaccines
by: Andrew D. Wiese, et al.
Published: (2016-06-01)

Radiographically confirmed community-acquired pneumonia in hospitalized adults due to pneumococcal vaccine serotypes in Sweden, 2016–2018—The ECAPS study
by: Karin Hansen, et al.
Published: (2023-02-01)

Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis
by: Hannah M.Garcia Garrido, et al.
Published: (2020-12-01)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
by: Matthew Wasserman, et al.
Published: (2019-03-01)